Key Highlights
- Proteome Sciences shares fell 5.17% on 16 September 2026.
- The company released its H1 2026 results today, showing Revenue broadly stable at £1.87 million.
- H1 loss after tax narrowed to £1.40 million from £2.14 million a year earlier.
- Proteomics services revenue fell 17% to £0.89 million in H1 because of project timing, but management expects a substantial increase in full-year services revenue.
- The number of services orders received during H1 2026 increased 32%, with their value almost equal to the entire services revenue generated during 2025.
- TMT reagent sales and royalties increased to £0.98 million, compared with £0.79 million in H1 2025.
- Cash resources increased to £1.10 million at 30 June 2026, from £0.78 million at the end of 2025.
- On 15 September, Proteome Sciences secured another significant GCLP chemoproteomics contract, the third contract connected with the same protein for global Phase 1 and Phase 2 trials.
Why Is Proteome Sciences Stock in Focus Today?
Proteome Sciences has moved into focus on 16 September 2026, with LSE:PRM down 5.17%.
The timing is notable because the company released its H1 2026 results today, while also entering the day with a fresh clinical contract announced on 15 September.
The latest numbers show a Business undergoing a transition. Overall revenue remained broadly flat, but costs were reduced, the loss narrowed materially and the number of new services orders increased strongly.
The central question for investors is whether the growing order pipeline can convert into significantly higher services revenue during the second half of 2026.
Why Did LSE:PRM Fall 5.17% Today?
There is no clear evidence of a new negative operational development explaining the 5.17% decline.
In fact, the latest company developments include several positive operational indicators.
The H1 results showed improved gross profit, lower costs and a narrower loss, while yesterday's announcement confirmed another GCLP chemoproteomics contract.
The share-price decline may therefore reflect short-term trading dynamics and investor reaction to the H1 revenue mix rather than a new deterioration in the underlying business.
The company's shares have also experienced considerable Volatility during 2026, meaning daily percentage movements can be significant.
What Did Proteome Sciences Report in H1 2026?
Total revenue increased marginally to £1.87 million, from £1.86 million in H1 2025.
However, the revenue mix changed considerably.
Proteomics services revenue fell to £0.89 million from £1.07 million, while TMT reagent sales and royalties increased to £0.98 million from £0.79 million.
Gross profit improved to £0.44 million from £0.32 million, while cost of sales and administrative expenses fell 11% to £3.11 million.
As a result, the loss after tax narrowed to approximately £1.40 million from £2.14 million.
This shows improving cost control despite relatively limited headline revenue growth.
Why Is the Services Order Pipeline Important?
The most significant operational feature of the H1 results was the growth in new orders.
Proteome Sciences reported that the number of services orders increased 32% during the first half of 2026.
Importantly, the total value of those orders was almost equal to the company's entire services revenue for FY2025.
Management attributed the lower H1 services revenue primarily to timing, rather than a deterioration in demand, and expects higher volumes of sample processing and shipments from its Frankfurt laboratory during H2.
This creates an important second-half revenue conversion opportunity.
What Is Driving Demand for Proteomics Services?
Proteome Sciences provides specialist mass-spectrometry-based services for drug discovery, clinical development and biomarker identification.
The company has increasingly focused on GCLP-compliant services, particularly for pharmaceutical and biotechnology customers conducting clinical trials.
Management said the move toward targeted proteomics is supporting demand because mass spectrometry can measure proteins and post-translational modifications in areas where conventional antibody-based assays may not be available.
The Frankfurt facility's established GCLP accreditation is particularly relevant because clinical-stage contracts tend to be larger and can involve recurring sample shipments from multiple global testing sites.
Why Is the New GCLP Contract Important for LSE:PRM?
On 15 September, Proteome Sciences confirmed another significant GCLP chemoproteomics contract.
It is the third contract involving the same protein for ongoing global Phase 1 and Phase 2 clinical trials.
Samples are expected to begin arriving later in 2026, with most of the work expected to be completed during 2027.
The development provides evidence of repeat business from the same clinical programme and potentially gives greater revenue visibility into 2027.
It also reinforces the company's strategy of moving toward larger, clinical-stage proteomics projects.
What Is Chemoproteomics and Why Does It Matter?
Chemoproteomics uses proteomic techniques to study interactions between drugs and proteins.
For pharmaceutical companies, this can help identify drug targets, understand mechanisms of action and assess whether a treatment is interacting with the intended biological pathway.
Proteome Sciences has developed its own chemoproteomics workflows, including its Solvent Shift approach.
The company secured a further significant clinical contract for this platform in June, which it described as a precursor to a new clinical-trial programme later in 2026.
The subsequent September contract indicates that this service line is moving further into clinical applications.
What Is Happening With TMT Reagent Sales?
TMT reagent sales and royalties recovered during H1 2026.
TMT and TMTpro sales increased 68% year-on-year to £0.64 million, while royalties were £0.34 million.
Management linked the recovery partly to improving demand after the significant funding and budget pressures affecting the US research environment during 2025.
The company is also developing additional reagent products, including 96plex, 105plex and DXT isotopic DIA tags, which could provide additional licensing, Manufacturing and Royalty opportunities.
How Important Is Proteome Sciences' Cash Position?
Cash resources stood at approximately £1.10 million at 30 June 2026, compared with £0.78 million at 31 December 2025.
Operating cash outflow during H1 was approximately £0.43 million, substantially lower than the £0.90 million outflow recorded in H1 2025.
The improvement in Operating Cash Flow is important because Proteome Sciences remains loss-making and continues to invest in laboratory capacity, technology and new services.
The company also completed a fundraising in January 2026, raising approximately £0.97 million gross, with the proceeds intended to support new revenue streams and expansion of its services capability.
What Could Move LSE:PRM Next?
The key catalysts include:
- H2 2026 services revenue.
- Conversion of the growing services order book.
- Further GCLP contracts.
- Additional chemoproteomics projects.
- Sample shipments to the Frankfurt facility.
- Recovery in TMT reagent sales.
- New reagent launches.
- Growth in US customer activity.
- Cash-flow performance.
- Further clinical-trial contracts.
The most important near-term Factor is likely to be whether the strong H1 order intake converts into recognised revenue during H2 and into 2027.
Why Are Investors Watching LSE:PRM After the 5.17% Fall?
The 5.17% decline on 16 September 2026 comes despite several constructive developments.
The H1 loss narrowed, operating cash outflow improved, cash resources increased and the services order count rose 32%.
At the same time, services revenue itself declined during H1 because of timing, while the company remains loss-making and continues to require Capital to fund operations.
The latest GCLP contract provides another indication of demand from clinical-stage biopharma customers and should contribute mainly during 2027.
For LSE:PRM, the key issue is therefore revenue conversion: whether its expanding order pipeline and growing chemoproteomics activity can translate into sustained revenue growth and improving cash generation.
What Should Investors Watch for LSE:PRM?
The main indicators are H2 services revenue, GCLP sample volumes, new contract wins, TMT sales, recurring customer activity and operating cash flow.
The company's ability to turn its stronger order intake into revenue will be particularly important.
The 5.17% share-price decline therefore comes as Proteome Sciences enters a potentially important second half of 2026, with clinical proteomics and chemoproteomics contracts providing the main areas to monitor.






Please wait processing your request...